Skip to main content

Animations

Funded Studies

The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.

Search or browse funded studies

Previously funded studies appear chronologically, with the most recent appearing first.

Filters
From
To
  • ${value}

Filter Results (2353${count})

  • Defining Cognitive Phenotypes of Parkinson’s Disease, 2011
    Predicting Cognitive Profiles in Parkinson's Disease: A Multimodal Approach

    Objective/Rationale:
    Our proposal aims to determine the optimum combination of techniques to detect rate of cognitive decline in people with newly diagnosed Parkinson’s disease (PD). We will apply...

  • Defining Cognitive Phenotypes of Parkinson’s Disease, 2011
    The Relationship Between Cognitive Phenotypes of PD with Visual Hallucinations and 5HT2A Receptors in the Inferotemporal Cortex

    Objective/Rationale:
    The project aims to understand the mechanisms underlying cognitive deficits that are associated with visual hallucinations (VH) in Parkinson’s disease (PD). We have previously...

  • MJFF Research Grant, 2011
    Development of Hsf1 Effectors as Parkinson's Disease Therapeutics

    Objective/Rationale:
    This project focuses on the development of small molecule therapeutics to treat Parkinson’s disease by advancing lead compounds that elevate the abundance of protein chaperones....

  • Rapid Response Innovation Awards, 2011
    Transport and Transfer of Misfolded Alpha-synuclein in Neurons

    Objective/Rationale:
    Alpha-synuclein is a protein found in human neurons that can adopt a toxic form whose spread may be responsible for Parkinson’s disease. We showed that toxic alpha-synuclein is...

  • MJFF Research Grant, 2011
    Investigating Signaling Pathway Dysfunction Linked to LRRK2

    Promising Outcomes of Original Grant:
    Our project investigated whether LRRK2 had an impact on a particular signaling system in the cell called the mTOR pathway. This pathway helps to control how cells...

  • Therapeutics Development Initiative, 2011
    Delivery of GDNF to the Brain by Novel Nanovesicles for the Treatment of PD

    Objective/Rationale:
    GDNF has the potential to halt the progression of, or reverse, PD. However, GDNF, a large protein, does not get into the brain when given orally or intravenously. Our novel nano...

Two female doctors talking in the lab.

Apply for a Grant

Our funding programs support basic, translational and clinical research from academia and industry.

See Funding Opportunities
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.